Effect of ritanserin, specific 5HT-2 antagonist, on PRL secretion in normal subjects and in different hyperprolactinaemic conditions.

Abstract

The availability of a new specific anti 5HT-2 compound, ritanserin (RTS), led us to further investigate the role of serotonin in controlling PRL secretion. The drug was administered to normoprolactinaemic subjects and to patients with differing hyperprolactinaemic conditions. While RTS failed to modify PRL levels in normoprolactinaemic subjects and in patients with PRL-secreting pituitary adenomas, a marked decrease in the hormone was obtained in patients with functional and puerperal hyperprolactinaemia. The lack of effect of RTS in PRL-secreting pituitary adenomas suggests that the reported suppression of PRL by other antiserotoninergic drugs, such as metergoline, is probably due to their concomitant dopaminergic activity.

• Authors: P Falaschi, M Rosa, A Rocco, R D'Urso, A Proietti, G B Melis
• Journal: Clinical endocrinology (Clin Endocrinol (Oxf)) Vol. 34 Issue 6 Pg. 449-53 (Jun 1991) ISSN: 0300-0664 [Print] England
• PMID: 1909607 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Piperidines
• Serotonin Antagonists
• Ritanserin
• Sulpiride
• Prolactin

Topics

• Adenoma (metabolism)
• Female
• Follicular Phase (physiology)
• Humans
• Hyperprolactinemia (drug therapy, physiopathology)
• Piperidines (pharmacology, therapeutic use)
• Pituitary Neoplasms (metabolism)
• Postpartum Period (blood)
• Pregnancy
• Prolactin (metabolism)
• Ritanserin
• Serotonin Antagonists (pharmacology, therapeutic use)
• Single-Blind Method
• Sulpiride (pharmacology)